A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/2
75
about 7.6 years
≤25
20 sites in CA, CO, FL +12
About this study
This trial is testing a treatment called repotrectinib to see if it's safe and effective for children and young adults with certain types of cancer. The goal is to find the best dose level and determine if this drug can help fight the cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Oral repotrectinib (TPX-0005)
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
repotrectinib
oral (Oral Capsule)
Primary: Overall Response Rate (ORR) (Phase 2)
Secondary: Area under the concentration versus time curve of repotrectinib in plasma (AUC), Central Nervous System Progression-Free Survival (CNS-PFS) (Phase 2), Duration of response (DOR) (Phase 1 and Phase 2), Intracranial objective response rate (IC-ORR) (Phase 1 and Phase 2), Maximum concentration of repotrectinib in plasma (Cmax), Overall Response Rate (ORR) (Phase 1), Overall survival (OS) (Phase 2), Progression-free survival (PFS) (Phase 2)
Oncology